Home » Stocks » AMED

Amedisys Inc. (AMED)

Stock Price: $293.89 USD 6.03 (2.09%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 9.48B
Revenue (ttm) 2.02B
Net Income (ttm) 166.11M
Shares Out 32.66M
EPS (ttm) 4.99
PE Ratio 58.87
Forward PE 47.62
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $293.89
Previous Close $287.86
Change ($) 6.03
Change (%) 2.09%
Day's Open 288.18
Day's Range 286.82 - 294.56
Day's Volume 123,900
52-Week Range 137.21 - 307.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 2 weeks ago

BATON ROUGE, La., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusse...

Zacks Investment Research - 2 weeks ago

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 3 weeks ago

BATON ROUGE, La., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America's leading independent home health, hospice and personal care company, today announced that its Board ...

Zacks Investment Research - 1 month ago

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 month ago

BATON ROUGE, La., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusse...

Zacks Investment Research - 1 month ago

Amedisys (AMED) continues to benefit from the recent acquisitions of hospice care providers.

GlobeNewsWire - 2 months ago

BATON ROUGE, La., Nov. 10, 2020 (GLOBE NEWSWIRE) --  Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kuss...

GlobeNewsWire - 2 months ago

BATON ROUGE, La., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusse...

Seeking Alpha - 2 months ago

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research - 2 months ago

An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.

Seeking Alpha - 2 months ago

Amedisys, Inc.'s (AMED) CEO Paul Kusserow on Q3 2020 Results - Earnings Call Transcript

Forbes - 2 months ago

After a 82% rise since the March 16 lows of this year, at the current price of around $249 per share we believe Amedisys stock, a home health and hospice care company, has reached its near-ter...

Zacks Investment Research - 2 months ago

Amedisys (AMED) delivered earnings and revenue surprises of 76.38% and 2.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Amedisys (NASDAQ:AMED) fell 2.7% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 94.78% year over year to $2.24, which beat t...

GlobeNewsWire - 2 months ago

BATON ROUGE, La., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2020.

Zacks Investment Research - 2 months ago

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 months ago

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS He...

Other stocks mentioned: CVS, MTH, NSP, VRTX
GlobeNewsWire - 3 months ago

BATON ROUGE, La., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the third quarter ended September 30, 2020, after the market ...

Zacks Investment Research - 3 months ago

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 4 months ago

BATON ROUGE, La., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kus...

Zacks Investment Research - 4 months ago

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 4 months ago

Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.

GlobeNewsWire - 4 months ago

BATON ROUGE, La., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, has signed a Care Coordinatio...

Zacks Investment Research - 4 months ago

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.

Seeking Alpha - 5 months ago

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.

Benzinga - 5 months ago

Shares of Amedisys (NASDAQ:AMED) were flat in after-market trading after the company reported Q2 results.

Zacks Investment Research - 5 months ago

Amedisys (AMED) delivered earnings and revenue surprises of 69.62% and 4.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

BATON ROUGE, La., July 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period ended June 30, 2020.

Zacks Investment Research - 5 months ago

Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Investors Business Daily - 5 months ago

Amedisys is expected to report earnings on Jul. 28. Amedisys now trading 2% below the 218.54 buy point from a fourth-stage consolidation that it cleared earlier.

Zacks Investment Research - 5 months ago

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.

GlobeNewsWire - 5 months ago

BATON ROUGE, La., July 16, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the second quarter ended June 30, 2020, after the market cl...

Zacks Investment Research - 6 months ago

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors Business Daily - 6 months ago

Lululemon, Fortinet, Inphi, Costco Wholesale and Amedisys are leading stocks to watch, all in or near buy zones.

Other stocks mentioned: FTNT, LULU, COST, IPHI
Zacks Investment Research - 6 months ago

ADUS vs. AMED: Which Stock Is the Better Value Option?

Other stocks mentioned: ADUS
Zacks Investment Research - 6 months ago

Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.

Zacks Investment Research - 6 months ago

DGX vs. AMED: Which Stock Is the Better Value Option?

Other stocks mentioned: DGX
GlobeNewsWire - 6 months ago

BATON ROUGE, La., June 17, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kus...

24/7 Wall Street - 7 months ago

With the first half of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the second half of the year, with what sh...

Other stocks mentioned: BMRN, HAE, HZNP, ZBH
Zacks Investment Research - 7 months ago

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 7 months ago

BATON ROUGE, La., June 05, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kus...

Zacks Investment Research - 7 months ago

Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.

GlobeNewsWire - 7 months ago

BATON ROUGE, La., June 01, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and personal care, announced today that, through one of its wholl...

Zacks Investment Research - 7 months ago

There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.

Other stocks mentioned: BKD, CHE, ENSG
Seeking Alpha - 8 months ago

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.

About AMED

Amedisys, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patie... [Read more...]

Industry
Medical Care Facilities
Founded
1982
CEO
Paul Kusserow
Employees
21,000
Stock Exchange
NASDAQ
Ticker Symbol
AMED
Full Company Profile

Financial Performance

In 2019, Amedisys's revenue was $1.96 billion, an increase of 17.63% compared to the previous year's $1.66 billion. Earnings were $126.83 million, an increase of 6.27%.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for Amedisys stock is "Buy." The 12-month stock price forecast is 306.57, which is an increase of 4.31% from the latest price.

Price Target
$306.57
(4.31% upside)
Analyst Consensus: Buy